HP 002
Alternative Names: HP-002Latest Information Update: 03 Jul 2025
At a glance
- Originator Shanghai Helioson Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Agammaglobulinaemia tyrosine kinase degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 03 Jul 2025 Preclinical trials in Haematological malignancies in China (unspecified route)
- 25 Apr 2025 Pharmacokinetics and pharmacodynamics data from a preclinical studies in hematological malignancies presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)